EPAG UPDATE. Lenja Wiehe. European Patient Advocacy Groups Manager, EURORDIS

Similar documents
the patients perspective and role of epags

The EU rare diseases policy framework: the context for ERNs

Meeting with EMA: cooperation in the field of ERNs. Enrique Terol DG SANTE European Commission

National Clinical Programme for Rare Diseases Prof. Eileen Treacy April 7 th,

STRATEGIC APPROACH & WORKPLAN 2007

SNOMED CT EXPO 2017 Bratislava, 19 October 2017

NORDIC CONFERENCE ON RARE DISEASES

PHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe

Transparency in drug regulatory decision making Why transparency? Birthe Byskov Holm, Rare Diseases Denmark Copenhagen October

rare diseases research through National Plans and Strategies

EUCERD Recommendations on Rare Disease European Reference Networks (RD ERNs)

Table Of Content. European Organisation for Rare Diseases... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...

The basics a. Mission Statement (unchanged) eurordi s.org

During the Health Issues Centre conducted a project for the Ministerial Taskforce for Cancer. This project aimed to:

DRAFT STRATEGIC APPROACH & ACTION PLAN For consultation at RDI Annual Meeting Edinburgh, Scotland May 25, 2016

The European Reference Network in Rare Hematological Diseases

Updates from the European Centre for Disease Prevention and Control

Table Of Content. EURORDIS_FY Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7

Building the European Reference Network for Rare Endocrine Conditions (Endo-ERN) Journee Annuelle, FIRENDO, Paris, 14 december 2016

Introduction. Legislation & Policy Context

E-RARE & THE EUROPEAN JOINT PROGRAMME ON RARE DISEASES. RE(ACT) 2018 Congress 7-10 of March 2018 Bologna, ITALY

Public Engagement and Public and Patient Involvement. NIHR Newcastle Biomedical Research Centre and Biomedical Research Unit

Engaging People Strategy

STRATEGIC PLAN

Not Myself Today Europe Project Development

DRAFT STRATEGIC APPROACH & ACTION PLAN For consultation at RDI Annual Meeting Edinburgh, Scotland May 25, 2016

Adding Value to the NHS, Health and Care, through Research Management, Support & Leadership

Consumer Participation Strategy

RARE-Bestpractices Project. Final Conference

COMMISSION OF THE EUROPEAN COMMUNITIES

British Association of Stroke Physicians Strategy 2017 to 2020

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation

ACTION PLAN Adoption Annual Activity & Financial Report 2018 Adoption Work Programme: Action Plan & Budget 2019

International Kidney Cancer Coalition. Patient Organisations Working Together Globally to Support Those Affected by Kidney Cancer

Joint Programming in Neurodegenerative Disease Research (JPND)

IARC A UNIQUE AGENCY. Cancer research for cancer prevention

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary

Table Of Content. SSI_FY Summary... 3 Coordinator, Leader contact and partners... 7 Outputs... 8

Transforming health through IT

Table Of Content. European Rare Kidney Diseases Reference Network... 2 Summary... 3 Work Package... 9

Committee of Senior Representatives Tenth Meeting Oslo, Norway 11 December 2006

London Association of Directors of Public Health Priorities for Collaboration September 2017 September 2018

2016 NYC Hep B Coalition Work Plan

The American College of Obstetricians and Gynecologists Office of Global Women s Health Strategic Plan

Strategic Plan Overview

Peer Networks 101. The Role of a Statewide Network 07/31/2018. Cameron Wood, CRPS-A Executive Director Peer Support Coalition of Florida, Inc.

EU Funding for Global Health Research and Development (GH R&D) Cecile Vernant, Head of EU Advocacy, DSW EU 13 June 2014

Joint Programming Initiative on Neurodegenerative Diseases. Prof. Philippe Amouyel Chair, JPND Management Board

RD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS

CROSS LINKING EUROPEAN REFERENCE NETWORKS

State of the Art of Rare Disease Activities in EU Member States and Other European Countries. Slovak Republic Report

Addressing Gaps in MS Care. November 6, :00 AM - Noon

European Patients Academy on Therapeutic Innovation

Patient and Carer Network. Work Plan

Rare Cancer Perspective in the EUCERD

15571/17 YML/ik 1 DG C 1

TABLE of Contents. EURORDIS in brief

Table Of Content. Outputs... 9

EUROPLAN National Conferences and Post-NCs activities in support to Member States

Comprehensive Cancer Control Technical Assistance Training and Communication Plan. PI: Mandi Pratt-Chapman, MA. Cooperative Agreement #1U38DP

State of the Art of Rare Disease Activities in EU Member States and Other European Countries. Hungary Report

Pfizer Support to European and International Patient Organisations in 2008

CORPORATE REPORT Communication strategy

Simply, participation means individual s involvement in decisions that affect them.

Table Of Content. Outputs... 8

Cochrane Rehabilitation Report sullo stato attuale di Cochrane Rehabilitation field e prospettive future nell ottica di ISPRM

WHY PATIENT ASSOCIATIONS SHOULD WORK INSIDE METABERN. MAURIZIO SCARPA, Anne-Sophie Lapointe (PhD) Coordinator MetabERN, epag PO

Objectives Measurable Indicators Means of Verification Important Assumptions Goal To promote an inclusive society where

NATIONAL REGISTRIES OF RARE DISEASES IN EUROPE: AN OVERVIEW BY THE EPIRARE PROJECT.

Queen Margaret University, Edinburgh DRAFT British Sign Language (BSL) Action Plan

MRCG Strategic Document

Towards Integrated Syndromic Surveillance in Europe?

2018 AFP INTERNATIONAL COMMITTEE DESCRIPTIONS

Madrid, Feb 2-4, 2012

BMA knowledge sharing event with patient/lay groups

EFFECTIVENESS IN CONSUMER GOVERNANCE

Title Corporate Parenting Plan

Patient and Public Involvement and Engagement (PPI/E) Strategy

Strategy for Personal and Public Involvement (PPI)

On behalf of E-PILEPSY consortium Philippe Ryvlin (Lyon, France)

Strategic Operational Research Plan February 13, Scientific Office Digestive Health Strategic Clinical Network

Tuberous Sclerosis Australia Strategic Plan

Advocacy Strategy

From CF Adult and Family Advisors (AFA) to Community Voice

Integrated Diabetes Care in Oxfordshire -patient's perspective. Avril Surridge

Scientific Council Fifty-first Session 21/11/2014

RESPECT Project CASE STUDY

An Active Inclusive Capital. A Strategic Plan of Action for Disability in London

European Dietetic Action Plan Progress report 2017

Retina International General Assembly Auckland, New Zealand

Canadian Mental Health Association Nova Scotia Division. Strategic Plan (last updated: June 28, 2016 TW; July 4, 2016 PM)

Need for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines

Child Neurology Foundation

Europa Donna in Europe and in Slovenia

EFSA cross-cutting guidance lifecycle. European Food Safety Authority (EFSA), Daniela Maurici, Raquel Garcia Matas, Andrea Gervelmeyer

AUSTRALIAN AND NEW ZEALAND STILLBIRTH ALLIANCE. A regional office of the International Stillbirth Alliance

DRUG AND ALCOHOL TREATMENT ACTIVITY WORK PLAN

The EUQPPV Organisation: progress to date Objectives of this session

Skin Health for the World

Patient and Public Engagement Strategy

Transcription:

EPAG UPDATE Lenja Wiehe European Patient Advocacy Groups Manager, EURORDIS

Patient Centre & Empowerment European Reference Networks (ERNs) created on founding principles of patient-centred care, patient advocate empowerment, patient engagement European Patient Advisory Groups (epag): 24 forums for dialogue, unity & solidarity to optimise involvement of patients Represent patients to engage in application process & governance of RD ERNs Open to members & non-member patient groups in EU Aligned with RD ERN scope Composed of >150 elected epag reps & <1000 epag member organisations Voting Members of ERN Boards, equal voice! Recruitment continue for ALL disease specific clinical networks / committees and transversal working groups 31/10/2017 2

Patient & Clinical Partnership, Vilnius 9-10 March 2017 +50 number. epag Representatives attended Vilnius, funded by the EC as ERN representatives

ERN Blueprint for Patient Involvement Input into ERN Board: Identify potential partners and existing stakeholders Strategic planning including expand network scope and coverage Monitors the activity, outcomes, and initiatives of the Network Established mechanisms to hear from and incorporate the voice and opinion of patients and families Develops and provides access to information adapted to the specific needs of patients Standardised common patient experience tool Improve the safety and quality of care base on patients experience Research Activities Knowledge Generation & Dissemination Training & Education Data Sharing: Promotes and/or facilitates the use of information and communication technology Virtual consultation and share expertise with local hospitals Specialist Advice Target Improvements in Rare Diseases Research Set research priorities Supports collaborative research Disseminate research project information and results Recruitment to clinical trials and studies Shared registries and databases Knowledge Generation & Dissemination Establish patient pathways and cross-border pathways based on patient needs Develop, disseminate and implement guidelines and protocols Review and disseminates expertise, best practice and evidence Discuss new treatments, therapies, and health care technologies Training & Education Provides education and training Share experience, exchange knowledge and best practice and expertise within ERN, between ERNs and wider community Patient Care Inform patients and families about patient pathways Disseminates information on patient safety standards and safety measures Enabling reporting possible safety incidents or adverse events Source: EC AMT Operational Criteria for Networks

European Patient Advocacy Group Satellite Meeting

epag Guide : Foster Engagement & Involvement

Kick Off Meetings European Reference Network KOM date Location EURORDIS participation Rare Neuromuscular ERN Vilnius, Lithuania 10 March 2017 - Transplantation ERN Vilnius, Lithuania 10 March 2017 Yes Rare Haematological ERN Paris, France 26-27 Jan 2017 Yes Rare Eye ERN Tübingen, Germany 3-5 April 2017 Yes Rare Pulmonary ERN Frankfurt, Germany 5-6 April 2017 Yes Rare Neurology ERN Milan, Italy 15-16 April 2017 - Rare Gastrointestinal ERN Rotterdam, Netherlands 20-21 April 2017 Yes Rare Liver ERN Amsterdam, Netherlands 21 April 2017 Yes Adult Cancer ERN Lyon, France 21-22 April 2017 Yes Rare Metabolic ERN Frankfurt, Germany 24-25 April 2017 Yes Rare Endocrine ERN Leiden, Netherlands 27 March 2017 - Rare Kidney ERN* Heidelberg, Germany 22-23 May 2017 - Rare Bone ERN Rome, Italy 23-24 May 2017 Yes Rare Skin ERN Brussels, Belgium 25-26 May 2017 Yes * EURORDIS supported FEDER workshop in Amsterdam on 5 March 2017 7

Kick Off Meetings European Reference Network KOM date Location EURORDIS participation Genetic Tumour ERN Copenhagen, Denmark 27-28 May 2017 Yes Rare Connective Tissue ERN Pisa, Italy 26-28 May Yes Rare Epilepsies ERN London, UK 3 June 2017 Yes Rare Urogenital ERN Amsterdam, Netherlands 6 June 2017 Yes Craniofacial & ENT Rotterdam 10-11 June Yes Paediatric Cancer ERN* TBC June 2017 Yes Rare Immunodeficiency, Auto-inflammatory and Autoimmune ERN Rare Cardiac ERN : Board Meeting Edinburgh, Scotland 11 September 2017 Yes Barcelona, Spain 27 August 2017 Yes Rare Malformations ERN Manchester, UK 18 September Yes 2017 Rare Vascular ERN Paris, France 14 October 2017 Yes * EURORDIS supported Childhood Cancer International Conference in Rome on 12-14 June 2017 8

Establish a Patient Advisory Committee (PAC)

epag Leadership Programme Webinar Capacity buidling Transversal Focus Groups Across ERNs Peer Coaching epag focused Mentoring Programme individual focus Training courses 1. Virtual Healthcare; 2. Data Sharing; 3. Outcomes & Indicators; 4. Clinical Guidelines; 5. ERN & Orphan Drug Development 1. ERN Education & Training FG 2. ERN Research & Registries FG 3. ERN Outcomes & Guidelines FG Quarterly epag Coaching Groups with clinical lead Mentoring Programme: Pilot with 12 mentors 1. Presenting with Impact training; 2. Influencing without authority training 10

1 1 epag Mentoring Program A 12 months long pilot mentoring relationship where 12 mentors and 17 mentees dedicate a minimum of 2.5 hours every two months to the program Aim #1 Carefully consider strategic health advocacy processes, roles, and responsibilities Aim #3 Maintain or increase areas of impact in the board and committee environment Aim #2 Explore strategies in collaborating with clinicians and patient representatives for improvement Aim #4 Being conscious and aware of personal leadership strengths and areas of development Aim #5 Identify tactics, tools and strategies that promote communication, cooperation, networking and coordination strategies Aim #6 Being conscious and aware of personal leadership strengths and areas of development

Facebook Workplace Initiative An initiative launched by EURORDIS to create a common social media platform for epag representatives and patients organisations involved in the 24 epags. There are 48 communities for individual epag. Each epag community has two groups to: # Encourage communication across the epag Representatives group # Facilitate co-working within epags through the creation/modification and sharing of documents # Encourage internal communication between epag representatives and to wider patient communities # Facilitate large scale communications from in the epag Advocates group

ERN Common Patient Experience Survey Rare Barometer Voices is a panel of people living with a rare disease who participate regularly in EURORDIS surveys and studies available in 23 languages. Exploring the possible developing this platform to be the centralised patient feedback mechanism across the ERNs will provide information in order: To align strategic decisions and operational delivery of the ERNs with patients needs and experiences, specifically the development of healthcare pathways and treatment protocols; To enable ERNs to capture the experience and feedback of multisystem rare disease patients treated in one or multiple networks. Avoiding duplication of efforts through pooling of resources to drive economies of scale; Ensuring robust, comparable and independent validated data and results by using the same survey methodology across ERNs; Achieving sufficient survey sample size and coverage of the ERNs patient population. 13

RD Action (Joint Action for Rare Diseases) Very Useful websites http://www.rd-action.eu/europeanreference-networks-erns/coordinationof-rare-disease-erns/

Thank You